Etonogestrel 68mg implant
Phase 1Active 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Menstrual Symptoms
Conditions
Menstrual Symptoms
Trial Timeline
Apr 1, 2025 → Dec 1, 2025
NCT ID
NCT06775626About Etonogestrel 68mg implant
Etonogestrel 68mg implant is a phase 1 stage product being developed by Organon for Menstrual Symptoms. The current trial status is active. This product is registered under clinical trial identifier NCT06775626. Target conditions include Menstrual Symptoms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06775626 | Phase 1 | Active |
Competing Products
11 competing products in Menstrual Symptoms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elagolix + Estradiol /norethindrone acetate (E2/NETA) | AbbVie | Phase 3 | 77 |
| Atogepant + Placebo for Atogepant | AbbVie | Phase 3 | 77 |
| Marvelon | Merck | Approved | 85 |
| paroxetine | Novo Nordisk | Approved | 84 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Rimegepant + Placebo Comparator + Standard of Care + Rimegepant | Pfizer | Phase 3 | 76 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levetiracetam | UCB | Pre-clinical | 20 |
| Drospirenone and ethinyl estradiol + Placebo | Bayer | Pre-clinical | 20 |
| EE20/DRSP(YAZ, BAY86-5300) + Placebo | Bayer | Phase 3 | 74 |
| Vilaprisan (BAY1002670) | Bayer | Phase 3 | 74 |